{"id":2360,"date":"2026-10-05T12:59:10","date_gmt":"2026-10-05T07:29:10","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/glenmark-share-price-today-2026-10-05\/"},"modified":"2026-10-05T20:16:28","modified_gmt":"2026-10-05T14:46:28","slug":"glenmark-share-price-today-2026-10-05","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/glenmark-share-price-today-2026-10-05\/","title":{"rendered":"Why Glenmark Shares Fell 1.54% Today: Sector Consolidation | 5 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div data-approved-layout=\"1061-v1\" class=\"wt-article-v4\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: GLENMARK<\/strong> \u00b7 5 October 2026 \u00b7 Dated market coverage<\/p>\n<div style=\"flex-wrap:wrap;gap:7px;margin:8px 0 14px;\" class=\"wt-price-strip\">\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">Price<\/div>\n<div style=\"font-weight:900;color:#17324d;margin-top:2px;overflow-wrap:anywhere;\">\u20b92,295.00<\/div>\n<\/p><\/div>\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">Change<\/div>\n<div style=\"font-weight:900;color:#b42318;margin-top:2px;overflow-wrap:anywhere;\">-1.54%<\/div>\n<\/p><\/div>\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">High \/ Low<\/div>\n<div style=\"font-weight:900;color:#17324d;margin-top:2px;overflow-wrap:anywhere;\">\u20b92,340.00 \/ \u20b92,273.80<\/div>\n<\/p><\/div>\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">Prev. Close<\/div>\n<div style=\"font-weight:900;color:#17324d;margin-top:2px;overflow-wrap:anywhere;\">\u20b92,331.00<\/div>\n<\/p><\/div>\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">Volume<\/div>\n<div style=\"font-weight:900;color:#17324d;margin-top:2px;overflow-wrap:anywhere;\">4.85L<\/div>\n<\/p><\/div>\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">Updated<\/div>\n<div style=\"font-weight:900;color:#17324d;margin-top:2px;overflow-wrap:anywhere;\">03:15 PM<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<div style=\"background:#f7fbff;border:1px solid #cfe1f2;border-left:4px solid #2e7db2;border-radius:10px;padding:13px 15px;margin:12px 0 18px;\" class=\"wt-card\">\n<div style=\"font-weight:900;color:#1f4d70;margin-bottom:6px;\" class=\"wt-card-title\">Key Takeaways<\/div>\n<ul style=\"margin:0;padding-left:18px;\">\n<li>GLENMARK PHARMACEUTICALS was trading<strong>1.54% lower<\/strong>at \u20b92,295.00 and around the middle of the day&#8217;s trading range. <\/li>\n<li><strong>Likely reason:<\/strong>Routine sector consolidation and profit-taking following recent weakness. <\/li>\n<li>Cash volume was around<strong>87% of the 20-day average full-session volume<\/strong>, so participation remained below an average full session. <\/li>\n<\/ul><\/div>\n<h2>Why Glenmark Pharmaceuticals Shares Are Falling 1.54% Today<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Glenmark Pharmaceuticals declined 1.54% today, settling at \u20b92,295 after opening at \u20b92,326.10. The stock traded within a daily range of \u20b92,273.80 to \u20b92,340.00, finishing closer to the lower end of the session. Trading volumes remained relatively subdued, recording less than half of its 5-day average volume at around 485,236 shares traded, while the delivery percentage stood high at 67.37%.<\/p>\n<p class=\"wt-copy\">In the broader market context, the stock underperformed both the headline index and its sector. While the Nifty gained 0.60%, the Nifty Pharma index retreated 0.74%, and Glenmark&#8217;s decline mirrored the broader weakness in pharmaceutical equities. This downward session also extends a short-term consolidation phase for the counter, which has registered a 3.57% loss over the past five trading sessions and a 5.83% correction over the last 20 days.<\/p>\n<p class=\"wt-copy\">While no specific single corporate catalyst was announced today, the company continues to maintain focus on its regulatory compliance and international footprint, having recently secured a positive U.S. FDA Establishment Inspection Report for its Goa facility with a Voluntary Action Indicated classification in late September. This operational milestone follows ongoing specialty product launches globally, though the immediate price action reflects routine profit-taking and sector-wide consolidation following recent multi-month highs near \u20b92,537.<\/p>\n<\/div>\n<div style=\"border:1px solid #c9d9e7;border-left:5px solid #1f7b92;border-radius:10px;background:#f5fbfd;padding:14px 16px;margin:15px 0 20px;\" class=\"wt-card\">\n<div style=\"font-weight:900;color:#174c5d;margin-bottom:6px;\" class=\"wt-card-title\">Likely Reason for Today&#8217;s Move<\/div>\n<div style=\"font-weight:850;color:#20384a;margin-bottom:6px;\">Routine sector consolidation and profit-taking following recent weakness<\/div>\n<div style=\"\">The stock&#8217;s decline appears driven by broader pharmaceutical sector weakness and normal short-term profit-taking rather than any fresh negative corporate development. Low relative volume and lack of a same-day catalyst point toward standard technical retracement.<\/div>\n<ul style=\"margin:8px 0 0;padding-left:18px;\">\n<li>Nifty Pharma sector index fell 0.74% on the day<\/li>\n<li>Trading volume was subdued at 49% of its 5-day average<\/li>\n<li>Stock is down 3.57% over the past five sessions, indicating a continuation of recent consolidation<\/li>\n<\/ul><\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div style=\"gap:10px;margin:10px 0 22px;\" class=\"wt-card\">\n<div style=\"border:1px solid #dce5eb;border-radius:10px;padding:13px 14px;background:#fff;min-width:0;\">\n<div style=\"font-weight:900;color:#17324d;\">US FDA Establishes Inspection Report for Goa Facility<\/div>\n<div style=\"color:#708090;margin:3px 0 6px;\">23-Sep-2026<\/div>\n<div style=\"color:#34495d;\">Glenmark Pharmaceuticals announced the receipt of the Establishment Inspection Report (EIR) from the U.S. FDA for its manufacturing facility located in Goa. The inspection concluded with a Voluntary Action Indicated (VAI) classification, indicating satisfactory compliance with regulatory standards. This classification allows the facility to continue smooth export operations to the United States market without regulatory hurdles.<\/div>\n<\/p><\/div>\n<div style=\"border:1px solid #dce5eb;border-radius:10px;padding:13px 14px;background:#fff;min-width:0;\">\n<div style=\"font-weight:900;color:#17324d;\">Expansion of Global Respiratory Footprint in Brazil<\/div>\n<div style=\"color:#708090;margin:3px 0 6px;\">11-Sep-2026<\/div>\n<div style=\"color:#34495d;\">The company announced the official commercial launch of RYALTRIS in Brazil, marking a further expansion of its global respiratory innovation footprint. RYALTRIS is a fixed-dose combination nasal spray used for treating symptoms associated with allergic rhinitis. This market entry builds on the company&#8217;s strategy to scale up differentiated and branded respiratory products across key international geographies.<\/div>\n<\/p><\/div>\n<div style=\"border:1px solid #dce5eb;border-radius:10px;padding:13px 14px;background:#fff;min-width:0;\">\n<div style=\"font-weight:900;color:#17324d;\">U.S. Launch of Calcium Gluconate Injection Vials<\/div>\n<div style=\"color:#708090;margin:3px 0 6px;\">21-Aug-2026<\/div>\n<div style=\"color:#34495d;\">Glenmark Pharmaceuticals Inc., USA, announced the commercial introduction of Calcium Gluconate Injection USP across multiple dosage formats, including single-dose vials and pharmacy bulk packages. The rollout addresses critical hospital needs and adds to the company&#8217;s expanding injectable product portfolio in the North American region. The launch demonstrates execution capabilities in complex institutional segments.<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div style=\"gap:12px;margin:11px 0 22px;\">\n<div style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:5px solid #cc922c;border-radius:10px;padding:14px 15px;min-width:0;\" class=\"wt-card\">\n<div style=\"font-weight:900;color:#8c6318;margin-bottom:9px;\" class=\"wt-card-title\">Promoter Pledge \/ Encumbrance<\/div>\n<div style=\"gap:7px;\">\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"text-transform:uppercase;color:#74808d;font-weight:800;\">Promoter Holding<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:3px;\">46.65%<\/div>\n<div style=\"color:#71808d;margin-top:2px;\">46.65% previous qtr<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<div style=\"background:#f5f8fb;border:1px solid #d5e0ea;border-left:5px solid #6a849c;border-radius:10px;padding:14px 15px;min-width:0;\" class=\"wt-card\">\n<div style=\"font-weight:900;color:#405d76;margin-bottom:9px;\" class=\"wt-card-title\">Recent Ownership \/ Shareholding<\/div>\n<div style=\"gap:7px;\">\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"text-transform:uppercase;color:#74808d;font-weight:800;\">FII\/FPI<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:3px;\">20.89%<\/div>\n<div style=\"color:#71808d;margin-top:2px;\">20.34% previous qtr<\/div>\n<\/p><\/div>\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"text-transform:uppercase;color:#74808d;font-weight:800;\">Mutual Funds<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:3px;\">16.76%<\/div>\n<div style=\"color:#71808d;margin-top:2px;\">16.80% previous qtr<\/div>\n<\/p><\/div>\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"text-transform:uppercase;color:#74808d;font-weight:800;\">Institutional<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:3px;\">39.49%<\/div>\n<div style=\"color:#71808d;margin-top:2px;\">39.63% previous qtr<\/div>\n<\/p><\/div>\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"text-transform:uppercase;color:#74808d;font-weight:800;\">MF Schemes<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:3px;\">37<\/div>\n<div style=\"color:#71808d;margin-top:2px;\">36 previous qtr<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div style=\"border:1px solid #d5e0ea;border-radius:11px;background:#f7f9fc;padding:14px 15px;margin:10px 0 22px;\" class=\"wt-card\">\n<div style=\"color:#34495d;margin-bottom:10px;\">Mutual funds decreased their aggregate stake to<strong>16.76%<\/strong>from <strong>16.80%<\/strong>in the previous quarter. The number of disclosed MF\/UTI shareholders was 37, versus 36 in the previous quarter. <\/div>\n<div style=\"gap:8px;\">\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:9px;padding:10px 11px;min-width:0;\">\n<div style=\"font-weight:850;color:#20384a;\">HDFC MUTUAL FUND &#8211; HDFC MID-CAP FUND<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:4px;\">17.57M shares \u2022 6.22%<\/div>\n<div style=\"color:#74808d;margin-top:2px;\">30-JUN-2026<\/div>\n<\/p><\/div>\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:9px;padding:10px 11px;min-width:0;\">\n<div style=\"font-weight:850;color:#20384a;\">INVESCO INDIA CONTRA FUND<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:4px;\">6.22M shares \u2022 2.20%<\/div>\n<div style=\"color:#74808d;margin-top:2px;\">30-JUN-2026<\/div>\n<\/p><\/div>\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:9px;padding:10px 11px;min-width:0;\">\n<div style=\"font-weight:850;color:#20384a;\">BANDHAN NIFTY 200 MOMENTUM 30 INDEX FUND<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:4px;\">3.60M shares \u2022 1.28%<\/div>\n<div style=\"color:#74808d;margin-top:2px;\">30-JUN-2026<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<h2>Research &amp; Brokerage Views<\/h2>\n<div style=\"border:1px solid #cbd8ea;border-radius:11px;background:#f4f8fd;padding:13px 14px;margin:10px 0 22px;\" class=\"wt-card\">\n<div style=\"gap:8px;\">\n<div style=\"background:#fff;border:1px solid #dfe7f0;border-radius:9px;padding:10px 11px;min-width:0;\">\n<div style=\"font-weight:900;color:#21384f;\">Motilal Oswal<\/div>\n<div style=\"margin-top:4px;\"><strong>Buy<\/strong>\u2022 Target \u20b92,570 <\/div>\n<div style=\"color:#74808d;margin-top:2px;\">31 Aug 2026<\/div>\n<div style=\"color:#536273;margin-top:5px;\">Recommended as part of top stock picks by Chandan Taparia, reflecting confidence in the company&#8217;s fundamental positioning, specialty portfolio scaling, and technical upside.<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<div style=\"color:#6d7885;margin-top:8px;\">Third-party brokerage opinions; not WittyTrades recommendations.<\/div>\n<\/p><\/div>\n<h2>What to Watch Next<\/h2>\n<ul style=\"\">\n<li>Sustained delivery percentage trends near the 67% mark to gauge institutional accumulation<\/li>\n<li>Execution progress on recent international product rollouts including RYALTRIS in Latin America<\/li>\n<\/ul>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<h3 style=\"margin:13px 0 4px;\">Why is GLENMARK PHARMACEUTICALS share price falling today?<\/h3>\n<p style=\"margin:0;\" class=\"wt-copy\">The stock&#8217;s decline appears driven by broader pharmaceutical sector weakness and normal short-term profit-taking rather than any fresh negative corporate development. Low relative volume and lack of a same-day catalyst point toward standard technical retracement.<\/p>\n<h3 style=\"margin:13px 0 4px;\">How strong is trading participation today?<\/h3>\n<p style=\"margin:0;\" class=\"wt-copy\">Participation is moderate rather than exceptional. Volume is about 0.87x the latest 20-day average.<\/p>\n<div style=\"color:#606b78;border-top:1px solid #e1e7ef;padding-top:13px;margin-top:22px;\"><strong>Disclaimer:<\/strong>Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is informational and educational, not personalised investment advice or a recommendation. Market data may be delayed; verify current information before acting. <\/div>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/glenmark-share-price-today-2026-09-30\/\">Why Glenmark Shares Fell 4.4% Today: Sector Headwinds &amp; Volume Analysis \u2014 30 September 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/glenmark-share-price-today-2026-09-29\/\">Glenmark Pharma Shares Surge 5%: Why Glenmark Stock is Rising Today \u2014 29 September 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/glenmark\/\">More Glenmark Pharmaceuticals news and dated analysis \u2192<\/a><\/p>\n<p><strong>Article by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/glenmark-share-price-today-2026-10-05\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/glenmark-share-price-today-2026-10-05\/\"}, \"headline\": \"Why Glenmark Shares Fell 1.54% Today: Sector Consolidation | 5 October 2026\", \"description\": \"Glenmark Pharmaceuticals dropped 1.5% amid broader pharma sector weakness. Read analysis on price action, volume trends, and recent regulatory updates.\", \"datePublished\": \"2026-10-05T07:29:10Z\", \"dateModified\": \"2026-10-05T14:43:53.354897+00:00\", \"author\": {\"@type\": \"Organization\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"WittyTrades\", \"url\": \"https:\/\/www.wittytrades.com\/\"}, \"inLanguage\": \"en-IN\", \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/glenmark-company-news-2026-10-05.jpg\"]}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Glenmark Pharmaceuticals dropped 1.5% amid broader pharma sector weakness. Read analysis on price action, volume trends, and recent regulatory updates.<\/p>\n","protected":false},"author":1,"featured_media":2607,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Why Glenmark Shares Fell 1.54% Today: Sector Consolidation | 5 October 2026","_witty_meta_description":"Glenmark Pharmaceuticals dropped 1.5% amid broader pharma sector weakness. Read analysis on price action, volume trends, and recent regulatory updates.","_witty_primary_phrase":"Glenmark Pharmaceuticals share price 2026-10-05","_witty_reason_label":"Routine sector consolidation and profit-taking following recent weakness","_witty_reason_confidence":"low","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[37],"class_list":["post-2360","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-glenmark"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/2360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=2360"}],"version-history":[{"count":5,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/2360\/revisions"}],"predecessor-version":[{"id":2609,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/2360\/revisions\/2609"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/2607"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=2360"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=2360"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=2360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}